Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy

Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2019-12, Vol.145 (11), p.3101-3111
Hauptverfasser: Demontoux, Lucie, Derangère, Valentin, Pilot, Thomas, Thinselin, Chloé, Chevriaux, Angélique, Chalmin, Fanny, Bouyer, Florence, Ghiringhelli, François, Rébé, Cédric
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3111
container_issue 11
container_start_page 3101
container_title International journal of cancer
container_volume 145
creator Demontoux, Lucie
Derangère, Valentin
Pilot, Thomas
Thinselin, Chloé
Chevriaux, Angélique
Chalmin, Fanny
Bouyer, Florence
Ghiringhelli, François
Rébé, Cédric
description Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy are proposed to some patients. However, clinicians use different parameters of treatments without any consensus. Here we decided to evaluate the effect of osmolarity in the efficacy of this procedure to kill colon cancer cells. We first show that a short exposure of platinum derivatives in hypotonic conditions is more efficient to decrease cell viability of human and murine colon cancer cells in vitro as compared to isotonic conditions. This is related to more important incorporation of platinum and the capacity of hypotonic stress to induce the copper transporter CTR1 oligomerization. Oxaliplatin in hypotonic conditions induces caspase‐dependent cell death of colon cancer cells. Moreover, hypotonic conditions also modulate the capacity of oxaliplatin and cisplatin (but not carboplatin) to induce immunogenic cell death (ICD). In vivo, oxaliplatin in hypotonic conditions increases CD8+ T cell tumor infiltration and activation. Finally, in a murine peritoneal carcinomatosis model, oxaliplatin in hypotonic conditions is the only tested protocol which is able to slow down the appearance of tumor nodules and increase mice survival, while showing no effect in CD8+ T cells depleted mice or in immunodeficient mice. Altogether, our study provides new information both in vitro and in a preclinical model of peritoneal carcinomatosis, which highlights the importance of hypoosmolarity in intraperitoneal chemotherapy. What's new? Colorectal cancer can lead to peritoneal carcinomatosis, a terminal condition with only palliative treatments such as intraperitoneal chemotherapy currently available. To date, no consensus on treatment parameters exists. Here, hypotonic stress improves platinum derivatives‐induced cell death in human and murine colon cancer cell lines. A short exposition of cancer cells to oxaliplatin in hypotonic conditions was sufficient to induce immunogenic cell death. In a peritoneal carcinomatosis model, hypotonic conditions induced mice survival in a CD8+ T cell‐dependent manner. The findings suggest that oxaliplatin in hypotonic conditions, in the absence of hyperthermia, should be considered by surgeons practicing intraperitoneal chemotherapy.
doi_str_mv 10.1002/ijc.32590
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2265771490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2265771490</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3880-536eff1b85a419685ce5df9bc898b1fb2441bbd945b7c52e19e5ed57979695a73</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi1ERZfCgRdAlriUQ1rbiZP4iFaUFlXqBc6R40xYrxw72E5RHoc3ZZYUDkhcbI__b37N6CfkDWdXnDFxbY_mqhRSsWdkx5lqCia4fE52qLGi4WV9Tl6mdGSMc8mqF-S85GVViVrsyM_bdQ45eGtoyhFSouAP2htI1AQXPDWnIlIDztEBdD5Q64fFwED7lc5OZ-uXCZVoH_H9iH3aD9RO0-Kx_5s12rkV6zmGTcw2L1OIFMYRRbPSMKJljnpGD5wEtKPmAFPIB8DP9RU5G7VL8PrpviBfbz5-2d8W9w-f7vYf7gtTti0rZFmjI-9bqSuu6lYakMOoetOqtudjL6qK9_2gKtk3RgrgCiQMslGNqpXUTXlBLjdfnPT7Ail3k02ntbWHsKROiFo2Da8UQ_TdP-gxLNHjdJ0oWSmbCg-k3m-UiSGlCGM3RzvpuHacdafcOsyt-50bsm-fHJd-guEv-ScoBK434Id1sP7fqbv7vN8sfwHIQKXf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2303574035</pqid></control><display><type>article</type><title>Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Demontoux, Lucie ; Derangère, Valentin ; Pilot, Thomas ; Thinselin, Chloé ; Chevriaux, Angélique ; Chalmin, Fanny ; Bouyer, Florence ; Ghiringhelli, François ; Rébé, Cédric</creator><creatorcontrib>Demontoux, Lucie ; Derangère, Valentin ; Pilot, Thomas ; Thinselin, Chloé ; Chevriaux, Angélique ; Chalmin, Fanny ; Bouyer, Florence ; Ghiringhelli, François ; Rébé, Cédric</creatorcontrib><description>Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy are proposed to some patients. However, clinicians use different parameters of treatments without any consensus. Here we decided to evaluate the effect of osmolarity in the efficacy of this procedure to kill colon cancer cells. We first show that a short exposure of platinum derivatives in hypotonic conditions is more efficient to decrease cell viability of human and murine colon cancer cells in vitro as compared to isotonic conditions. This is related to more important incorporation of platinum and the capacity of hypotonic stress to induce the copper transporter CTR1 oligomerization. Oxaliplatin in hypotonic conditions induces caspase‐dependent cell death of colon cancer cells. Moreover, hypotonic conditions also modulate the capacity of oxaliplatin and cisplatin (but not carboplatin) to induce immunogenic cell death (ICD). In vivo, oxaliplatin in hypotonic conditions increases CD8+ T cell tumor infiltration and activation. Finally, in a murine peritoneal carcinomatosis model, oxaliplatin in hypotonic conditions is the only tested protocol which is able to slow down the appearance of tumor nodules and increase mice survival, while showing no effect in CD8+ T cells depleted mice or in immunodeficient mice. Altogether, our study provides new information both in vitro and in a preclinical model of peritoneal carcinomatosis, which highlights the importance of hypoosmolarity in intraperitoneal chemotherapy. What's new? Colorectal cancer can lead to peritoneal carcinomatosis, a terminal condition with only palliative treatments such as intraperitoneal chemotherapy currently available. To date, no consensus on treatment parameters exists. Here, hypotonic stress improves platinum derivatives‐induced cell death in human and murine colon cancer cell lines. A short exposition of cancer cells to oxaliplatin in hypotonic conditions was sufficient to induce immunogenic cell death. In a peritoneal carcinomatosis model, hypotonic conditions induced mice survival in a CD8+ T cell‐dependent manner. The findings suggest that oxaliplatin in hypotonic conditions, in the absence of hyperthermia, should be considered by surgeons practicing intraperitoneal chemotherapy.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.32590</identifier><identifier>PMID: 31344262</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Animals ; Antitumor activity ; Apoptosis ; Cancer ; Carboplatin ; Caspase ; CD8 antigen ; CD8-Positive T-Lymphocytes - drug effects ; CD8-Positive T-Lymphocytes - metabolism ; Cell activation ; Cell death ; Cell Line, Tumor ; Cell Survival - drug effects ; Cell viability ; Chemotherapy ; Cisplatin ; Colon cancer ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - immunology ; Colorectal cancer ; Colorectal carcinoma ; Female ; Gastric cancer ; HCT116 Cells ; HT29 Cells ; Humans ; hypotonic stress ; Immunodeficiency ; immunogenic cell death ; Immunogenicity ; Injections, Intraperitoneal ; Lymphocyte Activation - drug effects ; Lymphocytes ; Lymphocytes T ; Medical prognosis ; Medical research ; Metastases ; Mice ; Nodules ; Oligomerization ; Organs ; Osmolarity ; Osmotic Pressure ; Oxaliplatin ; Oxaliplatin - administration &amp; dosage ; Oxaliplatin - pharmacology ; peritoneal carcinomatosis ; Peritoneal Neoplasms - drug therapy ; Peritoneal Neoplasms - immunology ; Peritoneal Neoplasms - secondary ; Peritoneum ; Platinum ; platinum derivatives ; Surgery ; Xenograft Model Antitumor Assays</subject><ispartof>International journal of cancer, 2019-12, Vol.145 (11), p.3101-3111</ispartof><rights>2019 UICC</rights><rights>2019 UICC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3880-536eff1b85a419685ce5df9bc898b1fb2441bbd945b7c52e19e5ed57979695a73</citedby><cites>FETCH-LOGICAL-c3880-536eff1b85a419685ce5df9bc898b1fb2441bbd945b7c52e19e5ed57979695a73</cites><orcidid>0000-0002-5465-8305 ; 0000-0001-8831-145X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.32590$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.32590$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31344262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Demontoux, Lucie</creatorcontrib><creatorcontrib>Derangère, Valentin</creatorcontrib><creatorcontrib>Pilot, Thomas</creatorcontrib><creatorcontrib>Thinselin, Chloé</creatorcontrib><creatorcontrib>Chevriaux, Angélique</creatorcontrib><creatorcontrib>Chalmin, Fanny</creatorcontrib><creatorcontrib>Bouyer, Florence</creatorcontrib><creatorcontrib>Ghiringhelli, François</creatorcontrib><creatorcontrib>Rébé, Cédric</creatorcontrib><title>Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy are proposed to some patients. However, clinicians use different parameters of treatments without any consensus. Here we decided to evaluate the effect of osmolarity in the efficacy of this procedure to kill colon cancer cells. We first show that a short exposure of platinum derivatives in hypotonic conditions is more efficient to decrease cell viability of human and murine colon cancer cells in vitro as compared to isotonic conditions. This is related to more important incorporation of platinum and the capacity of hypotonic stress to induce the copper transporter CTR1 oligomerization. Oxaliplatin in hypotonic conditions induces caspase‐dependent cell death of colon cancer cells. Moreover, hypotonic conditions also modulate the capacity of oxaliplatin and cisplatin (but not carboplatin) to induce immunogenic cell death (ICD). In vivo, oxaliplatin in hypotonic conditions increases CD8+ T cell tumor infiltration and activation. Finally, in a murine peritoneal carcinomatosis model, oxaliplatin in hypotonic conditions is the only tested protocol which is able to slow down the appearance of tumor nodules and increase mice survival, while showing no effect in CD8+ T cells depleted mice or in immunodeficient mice. Altogether, our study provides new information both in vitro and in a preclinical model of peritoneal carcinomatosis, which highlights the importance of hypoosmolarity in intraperitoneal chemotherapy. What's new? Colorectal cancer can lead to peritoneal carcinomatosis, a terminal condition with only palliative treatments such as intraperitoneal chemotherapy currently available. To date, no consensus on treatment parameters exists. Here, hypotonic stress improves platinum derivatives‐induced cell death in human and murine colon cancer cell lines. A short exposition of cancer cells to oxaliplatin in hypotonic conditions was sufficient to induce immunogenic cell death. In a peritoneal carcinomatosis model, hypotonic conditions induced mice survival in a CD8+ T cell‐dependent manner. The findings suggest that oxaliplatin in hypotonic conditions, in the absence of hyperthermia, should be considered by surgeons practicing intraperitoneal chemotherapy.</description><subject>Animals</subject><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Carboplatin</subject><subject>Caspase</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes - drug effects</subject><subject>CD8-Positive T-Lymphocytes - metabolism</subject><subject>Cell activation</subject><subject>Cell death</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Cell viability</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - immunology</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>HCT116 Cells</subject><subject>HT29 Cells</subject><subject>Humans</subject><subject>hypotonic stress</subject><subject>Immunodeficiency</subject><subject>immunogenic cell death</subject><subject>Immunogenicity</subject><subject>Injections, Intraperitoneal</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Mice</subject><subject>Nodules</subject><subject>Oligomerization</subject><subject>Organs</subject><subject>Osmolarity</subject><subject>Osmotic Pressure</subject><subject>Oxaliplatin</subject><subject>Oxaliplatin - administration &amp; dosage</subject><subject>Oxaliplatin - pharmacology</subject><subject>peritoneal carcinomatosis</subject><subject>Peritoneal Neoplasms - drug therapy</subject><subject>Peritoneal Neoplasms - immunology</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Peritoneum</subject><subject>Platinum</subject><subject>platinum derivatives</subject><subject>Surgery</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFu1DAQhi1ERZfCgRdAlriUQ1rbiZP4iFaUFlXqBc6R40xYrxw72E5RHoc3ZZYUDkhcbI__b37N6CfkDWdXnDFxbY_mqhRSsWdkx5lqCia4fE52qLGi4WV9Tl6mdGSMc8mqF-S85GVViVrsyM_bdQ45eGtoyhFSouAP2htI1AQXPDWnIlIDztEBdD5Q64fFwED7lc5OZ-uXCZVoH_H9iH3aD9RO0-Kx_5s12rkV6zmGTcw2L1OIFMYRRbPSMKJljnpGD5wEtKPmAFPIB8DP9RU5G7VL8PrpviBfbz5-2d8W9w-f7vYf7gtTti0rZFmjI-9bqSuu6lYakMOoetOqtudjL6qK9_2gKtk3RgrgCiQMslGNqpXUTXlBLjdfnPT7Ail3k02ntbWHsKROiFo2Da8UQ_TdP-gxLNHjdJ0oWSmbCg-k3m-UiSGlCGM3RzvpuHacdafcOsyt-50bsm-fHJd-guEv-ScoBK434Id1sP7fqbv7vN8sfwHIQKXf</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Demontoux, Lucie</creator><creator>Derangère, Valentin</creator><creator>Pilot, Thomas</creator><creator>Thinselin, Chloé</creator><creator>Chevriaux, Angélique</creator><creator>Chalmin, Fanny</creator><creator>Bouyer, Florence</creator><creator>Ghiringhelli, François</creator><creator>Rébé, Cédric</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5465-8305</orcidid><orcidid>https://orcid.org/0000-0001-8831-145X</orcidid></search><sort><creationdate>20191201</creationdate><title>Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy</title><author>Demontoux, Lucie ; Derangère, Valentin ; Pilot, Thomas ; Thinselin, Chloé ; Chevriaux, Angélique ; Chalmin, Fanny ; Bouyer, Florence ; Ghiringhelli, François ; Rébé, Cédric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3880-536eff1b85a419685ce5df9bc898b1fb2441bbd945b7c52e19e5ed57979695a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Carboplatin</topic><topic>Caspase</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes - drug effects</topic><topic>CD8-Positive T-Lymphocytes - metabolism</topic><topic>Cell activation</topic><topic>Cell death</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Cell viability</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - immunology</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>HCT116 Cells</topic><topic>HT29 Cells</topic><topic>Humans</topic><topic>hypotonic stress</topic><topic>Immunodeficiency</topic><topic>immunogenic cell death</topic><topic>Immunogenicity</topic><topic>Injections, Intraperitoneal</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Mice</topic><topic>Nodules</topic><topic>Oligomerization</topic><topic>Organs</topic><topic>Osmolarity</topic><topic>Osmotic Pressure</topic><topic>Oxaliplatin</topic><topic>Oxaliplatin - administration &amp; dosage</topic><topic>Oxaliplatin - pharmacology</topic><topic>peritoneal carcinomatosis</topic><topic>Peritoneal Neoplasms - drug therapy</topic><topic>Peritoneal Neoplasms - immunology</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Peritoneum</topic><topic>Platinum</topic><topic>platinum derivatives</topic><topic>Surgery</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Demontoux, Lucie</creatorcontrib><creatorcontrib>Derangère, Valentin</creatorcontrib><creatorcontrib>Pilot, Thomas</creatorcontrib><creatorcontrib>Thinselin, Chloé</creatorcontrib><creatorcontrib>Chevriaux, Angélique</creatorcontrib><creatorcontrib>Chalmin, Fanny</creatorcontrib><creatorcontrib>Bouyer, Florence</creatorcontrib><creatorcontrib>Ghiringhelli, François</creatorcontrib><creatorcontrib>Rébé, Cédric</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Demontoux, Lucie</au><au>Derangère, Valentin</au><au>Pilot, Thomas</au><au>Thinselin, Chloé</au><au>Chevriaux, Angélique</au><au>Chalmin, Fanny</au><au>Bouyer, Florence</au><au>Ghiringhelli, François</au><au>Rébé, Cédric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>145</volume><issue>11</issue><spage>3101</spage><epage>3111</epage><pages>3101-3111</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy are proposed to some patients. However, clinicians use different parameters of treatments without any consensus. Here we decided to evaluate the effect of osmolarity in the efficacy of this procedure to kill colon cancer cells. We first show that a short exposure of platinum derivatives in hypotonic conditions is more efficient to decrease cell viability of human and murine colon cancer cells in vitro as compared to isotonic conditions. This is related to more important incorporation of platinum and the capacity of hypotonic stress to induce the copper transporter CTR1 oligomerization. Oxaliplatin in hypotonic conditions induces caspase‐dependent cell death of colon cancer cells. Moreover, hypotonic conditions also modulate the capacity of oxaliplatin and cisplatin (but not carboplatin) to induce immunogenic cell death (ICD). In vivo, oxaliplatin in hypotonic conditions increases CD8+ T cell tumor infiltration and activation. Finally, in a murine peritoneal carcinomatosis model, oxaliplatin in hypotonic conditions is the only tested protocol which is able to slow down the appearance of tumor nodules and increase mice survival, while showing no effect in CD8+ T cells depleted mice or in immunodeficient mice. Altogether, our study provides new information both in vitro and in a preclinical model of peritoneal carcinomatosis, which highlights the importance of hypoosmolarity in intraperitoneal chemotherapy. What's new? Colorectal cancer can lead to peritoneal carcinomatosis, a terminal condition with only palliative treatments such as intraperitoneal chemotherapy currently available. To date, no consensus on treatment parameters exists. Here, hypotonic stress improves platinum derivatives‐induced cell death in human and murine colon cancer cell lines. A short exposition of cancer cells to oxaliplatin in hypotonic conditions was sufficient to induce immunogenic cell death. In a peritoneal carcinomatosis model, hypotonic conditions induced mice survival in a CD8+ T cell‐dependent manner. The findings suggest that oxaliplatin in hypotonic conditions, in the absence of hyperthermia, should be considered by surgeons practicing intraperitoneal chemotherapy.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>31344262</pmid><doi>10.1002/ijc.32590</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-5465-8305</orcidid><orcidid>https://orcid.org/0000-0001-8831-145X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0020-7136
ispartof International journal of cancer, 2019-12, Vol.145 (11), p.3101-3111
issn 0020-7136
1097-0215
language eng
recordid cdi_proquest_miscellaneous_2265771490
source MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals
subjects Animals
Antitumor activity
Apoptosis
Cancer
Carboplatin
Caspase
CD8 antigen
CD8-Positive T-Lymphocytes - drug effects
CD8-Positive T-Lymphocytes - metabolism
Cell activation
Cell death
Cell Line, Tumor
Cell Survival - drug effects
Cell viability
Chemotherapy
Cisplatin
Colon cancer
Colonic Neoplasms - drug therapy
Colonic Neoplasms - immunology
Colorectal cancer
Colorectal carcinoma
Female
Gastric cancer
HCT116 Cells
HT29 Cells
Humans
hypotonic stress
Immunodeficiency
immunogenic cell death
Immunogenicity
Injections, Intraperitoneal
Lymphocyte Activation - drug effects
Lymphocytes
Lymphocytes T
Medical prognosis
Medical research
Metastases
Mice
Nodules
Oligomerization
Organs
Osmolarity
Osmotic Pressure
Oxaliplatin
Oxaliplatin - administration & dosage
Oxaliplatin - pharmacology
peritoneal carcinomatosis
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - immunology
Peritoneal Neoplasms - secondary
Peritoneum
Platinum
platinum derivatives
Surgery
Xenograft Model Antitumor Assays
title Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T11%3A47%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypotonic%20stress%20enhances%20colon%20cancer%20cell%20death%20induced%20by%20platinum%20derivatives%20and%20immunologically%20improves%20antitumor%20efficacy%20of%20intraperitoneal%20chemotherapy&rft.jtitle=International%20journal%20of%20cancer&rft.au=Demontoux,%20Lucie&rft.date=2019-12-01&rft.volume=145&rft.issue=11&rft.spage=3101&rft.epage=3111&rft.pages=3101-3111&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.32590&rft_dat=%3Cproquest_cross%3E2265771490%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2303574035&rft_id=info:pmid/31344262&rfr_iscdi=true